Navigation Links
Translational Science Expert, Dr. Melissa Ashlock, Joins aTyr Pharma to Advance Physiocrine-based Therapeutics
Date:5/18/2011

SAN DIEGO, May 18, 2011 /PRNewswire/ -- aTyr Pharma, an innovative protein therapeutics company, announced today that Melissa Ashlock, M.D., has joined as vice president, external scientific alliances and human genetics. Dr. Ashlock's experience in translating novel biology into drug discovery opportunities and collaborations will support the aTyr team in the development of innovative therapeutic approaches for Physiocrine-based medicines. Physiocrines are naturally occurring human proteins that possess novel in vivo biological activity as extracellular signaling molecules in known pathways relevant to developing protein therapeutics for a range of diseases.

Dr. John Mendlein, executive chairman of aTyr Pharma, said, "Dr. Ashlock's ability to advance new therapeutic applications from novel mechanisms will provide important insights as aTyr develops life-changing medicines for patients with grave conditions. Our opportunity at aTyr is to uncover the role of Physiocrines in modulating human physiology and intervening in disease, and we are excited to have Dr. Ashlock help us lead this effort."

"Through her previous leadership efforts in diseases like cystic fibrosis, Dr. Ashlock has demonstrated her ability to develop pivotal alliances and advance drug discovery processes to create potential high-value therapeutic candidates," said Dr. Jeff Watkins, CEO of aTyr Pharma. "The development of Physiocrine-based protein therapeutics is distinct from current protein therapeutic programs, and Dr. Ashlock's experience will be of great help as we create much-needed new medicines for breakthroughs in patient care."

Dr. Ashlock added, "Physiocrine protein pathways represent important new therapeutic intervention points for drug discovery. Genomics efforts have missed aminoacyl tRNA synthetases as a source of extracellular signaling molecules and the relevance of these proteins in therapeutics development has been overlooked. aTyr possesses a unique opportunity to treat grave diseases with innovative, high impact biologics. It is an honor to join such an outstanding scientific team to execute on their important mission."

Dr. Ashlock has recently served pharmaceutical companies and non-profit organizations to advance new drug discovery and development opportunities for unmet medical needs.  Since 1999, she has been involved with the Cystic Fibrosis Foundation (CFF), holding positions including vice president of drug discovery for its therapeutics affiliate, CFFT, and was part of the leadership team that helped transform cystic fibrosis (CF) venture philanthropy, a concept stemming from the visionary President and CEO Robert Beall, Ph.D. Dr. Ashlock also led the CFF's collaborative efforts to discover and develop drugs that addressed the basic defect in CF, including working with Vertex Pharmaceuticals on VX-770 and other approaches under investigation. Prior to CFF, she worked as a scientific investigator at the National Institutes of Health with Francis Collins, M.D., Ph.D., co-discoverer of the cystic fibrosis gene and Ron Crystal, M.D., a pioneer in gene therapy. She has been co-inventor or author of more than 50 issued patents and publications. She received her B.S. in biochemistry from Purdue University and her M.D. from Cornell University Medical College. She completed her medical residency at Dartmouth Medical School and is a licensed physician, board certified in adult internal medicine.

About Physiocrines

Physiocrines are derived from aminoacyl tRNA synthetases, which have been known for decades to function intracellularly in protein synthesis. Overlooked by genomic discovery efforts, Physiocrinesare extracellular proteins that modulate signaling pathways in a variety of physiological processes. These endogenous human proteins act through a variety of receptor classes via mechanisms distinct from current pharmaceuticals, and have potential applications in a number of therapeutic areas ranging from hematology and immunology, to metabolism disorders.

About aTyr Pharma

aTyr Pharma develops biologic therapeutics based on Physiocrines and is currently focusing on developing products for hematologic, immune, and metabolic indications. aTyr has established a dominant intellectual property estate surrounding Physiocrine-based compositions and potential therapeutic applications. The company's lead program, Tmax, is in preclinical development. The privately held biotech was founded by Scripps Research Institute Professor Paul Schimmel, a leading aminoacyl tRNA synthetase scientist, and is backed by leading life sciences investors Alta Partners, Cardinal Partners, Domain Associates and Polaris Ventures. For more information, please visit http://www.atyrpharma.com.


'/>"/>
SOURCE aTyr Pharma
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Janet Hammond Joins Roche as Vice President, Translational Medicine - Virology
2. AndroScience Corporation Awarded a $3.8 Million, 3-Year Milestone-Driven, Cooperative Translational Research Grant from the NIH to Develop an Oral Treatment for Spinal Bulbar Muscular Atrophy (Kennedys Disease)
3. Research Published in Science Translational Medicine Underscores Value of Depression Gene Therapy License Held by Neurologix
4. Childrens Hospital Boston and Particle Sciences Cooperate on Translational Medicine Efforts
5. Mike Burgess Named Head of Oncology Discovery Translational Area for Roches Pharma Research and Early Development (pRED) Organization
6. The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies
7. CTMM Becomes One of the Worlds Largest Public-Private Partnerships in Translational Medical Research
8. Adlyfe Strikes Translational Medicine Partnership With Wyeth Pharmaceuticals for Alzheimers Biomarker Assay
9. Oncolytics Biotech Inc. Announces Start of Patient Enrolment in Translational Clinical Trial Investigating REOLYSIN(R) in Patients with Metastatic Colorectal Cancer
10. Michael J. Fox Foundation Announces $11 Million in 2009 Funding for Translational, Pre-Clinical and Clinical Parkinsons Disease Research
11. Queens University Chooses Xceeds Ziplex(R) System for Translational Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... 12, 2016  Sequent Medical, Inc. announced today that ... evaluate the safety and effectiveness of the WEB™ Aneurysm ... intracranial aneurysms.  Prof Laurent Spelle , MD, Head ... Paris, France and Principal Investigator of the ... France and Germany.  Although patients with ruptured ...
(Date:2/12/2016)... 2016  OMS Supply, a large provider of oral ... today the recent launching of their new company website. ... features that enhance the user experience and enable practitioners ... --> --> Despite the ... that started in early 2016, they have already made ...
(Date:2/11/2016)... Feb. 11, 2016 - ... in Personalized Medicine and Cancer Therapy. - European ... Diagnostic Testing Markets. - Key Diagnostic Testing Markets. ... Molecular Diagnostics in Genetic Testing. - Molecular Diagnostics ... - Over-the-Counter Diagnostic Products World Markets. - ...
Breaking Medicine Technology:
(Date:2/13/2016)... ... 2016 , ... DDi , a Makro company, makes ... its expertise in eClinical Solutions. DDi has built its solution competency with a ... global clients. DDi provides smarter technology for Clinical Development, Regulatory and Enterprise domains ...
(Date:2/12/2016)... ... February 12, 2016 , ... The law firm of ... Evangeline Parishes. The purpose of these scholarships is to encourage applicants to pursue ... to seek employment within these two parishes. , “We have available jobs in ...
(Date:2/12/2016)... Falls Church, VA (PRWEB) , ... February 12, 2016 , ... CDRH Enforcement Trends: , ... http://www.fdanews.com/cdrhenforcementtrends , As Winston Churchill said, “Those who don’t learn ... 2015 will show what to expect when they come knocking this year. But that takes ...
(Date:2/12/2016)... Angeles, CA (PRWEB) , ... February 12, 2016 , ... ... With a hectic schedule, a demanding job, and no time to decompress, Rabinowitz found ... she dedicated herself to meditation for its impact on her life, implementing a 20-minute-per-day ...
(Date:2/12/2016)... ... February 12, 2016 , ... The ... Zuckerberg San Francisco General Hospital on April 5-7. The series is a multi-day, ... new habits. The workshops cover a broad range of topics, including coaching skills, ...
Breaking Medicine News(10 mins):